David Moss, Founder of InMuneBio
A brief history of Alzheimer's Disease:
- 1906: Discovery of brain disease → later named Alzheimer's disease in 1910
- 1976: Neurologist Robert Katzman identifies Alzheimer's as the most common cause of dementia and a public health challenge
- 1983: Researchers George Glenner and Cai'ne Wong identify beta-amyloid, a key component of Alzheimer's brain plaques
- 1986: Discovery of tau protein as a key component of tangles in Alzheimer's disease
- 1987: First clinical trial and detection of the first inherited Alzheimer's gene
- The 1990s: Establishment of a nationwide medical network for clinical research, the discovery of the first risk factor gene, and FDA approval of the first Alzheimer's drug
- 2012: Launch of the first major clinical trial
- 2013: Discovery of a new genetic risk factor
- 2015: Higher-than-expected deaths from Alzheimer's
- 2019: Initial signs of progress
- 2021: FDA approves the first drug treatment for Alzheimer's disease after 115 years since the disease's discovery.
This history could be more encouraging, but thankfully, it's only part of the research picture. With me today is David Moss from InMuneBio, a research company looking at firing up the immune cells in our brains to help fight Alzheimer's.
InmuneBio has completed a stage one clinical trial with good results, which excites me to share their story with you.
Now to pay some bills!
Make Your Brain Span Match Your LifeSpan
With Relevate nutritional supplement, you get science-backed nutrition to help protect your brain power today and for years to come. You deserve a brain span that lasts as long as your lifespan.
Join Fading Memories On Social Media!
If you've enjoyed this episode, please share this podcast with other caregivers! You'll find us on social media at the following links.
Contact Jen at email@example.com